Kyowa Kirin, the European subsidiary of the Japan-based specialty pharmaceutical company, and University Hospitals Birmingham NHS Foundation Trust have announced new findings from the ongoing PROCLIPI study on the treatment of cutaneous T cell lymphoma (CTCL) using POTELIGEO (mogamulizumab).
The PROCLIPI (PROgnostic Cutaneous Lymphoma International Prognostic Index) study is a prospective, observational, multicentre registry that now includes more than 2,000 patients across 19 countries – making it one of the largest CTCL data sets worldwide. Its primary objective is to collect robust clinical data to support the development of prognostic indices for CTCL.
“The PROCLIPI Study demonstrates the power of global collaboration in rare diseases. By bringing together data from across the world, we can generate insights that simply wouldn’t be possible in isolation,” said Professor Julia Scarisbrick, Chief Investigator of the PROCLIPI Study and Honorary Professor of Dermatology, University Hospitals Birmingham NHS Foundation Trust.
“We are working to build rigorous scientific evidence while giving patients and their families a better understanding of what long-term survival looks like.”
The latest results, presented at the European Organisation for Research and Treatment of Cancer – Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting in Athens, Greece, focused on overall survival (OS) outcomes.
Findings showed that POTELIGEO was associated with statistically significant and clinically meaningful improvements in median OS among patients with mycosis fungoides (MF) and Sézary syndrome (SS) – two rare CTCL subtypes, which is itself a rare form of non-Hodgkin’s lymphoma that remains treatable but not curable.
“These insights into improved overall survival for patients living with CTCL mark an important step forward, providing a stronger clinical evidence base and reinforcing the value of international networks in rare disease research,” says Dr Nick Kronfeld, Head of Medical Affairs, Kyowa Kirin International.
“By working alongside scientific and patient communities in CTCL, we can gain a better understanding of real-world outcomes, enabling us to bring life-changing value to patients and families, not just today but over the long term.”